Literature DB >> 21222617

Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells.

Yi Wang1.   

Abstract

Lung cancer is a leading cause of death in human. Cancer stem cells have been regarded as basis for failure of current therapeutic options. Salinomycin was shown to kill these cancer stem cells in some types of cancer such as breast cancer and leukemia. The in vitro anticancer activities of salinomycin have been validated against the lung cancer cell line A549 via sulforhodamine B and colony formation assay. Salinomycin has been demonstrated to significantly rupture the in vitro lung cancer tumorospheres from ALDH positive A549 lung cells using flow cytometry. Expression of stem cell markers OCT-4, NANOG and SOX2 in ALDH positive A549 lung cells was decreased significantly by real-time RT-PCR analysis after 24 hour salinomycin treatment. Taken together, salinomycin may provide a promising approach for lung cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21222617     DOI: 10.2174/157340611794859307

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  35 in total

Review 1.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

2.  Ca2+ Selective Host Rotaxane Is Highly Toxic Against Prostate Cancer Cells.

Authors:  David B Smithrud; Lucas Powers; Jennifer Lunn; Scott Abernathy; Michael Peschka; Shuk-Mei Ho; Pheruza Tarapore
Journal:  ACS Med Chem Lett       Date:  2017-01-04       Impact factor: 4.345

Review 3.  PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.

Authors:  Pu Xia; Xiao-Yan Xu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 4.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

5.  Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest.

Authors:  Won Ki Kim; Ju-Hwa Kim; Kyungsil Yoon; Sunshin Kim; Jungsil Ro; Han Sung Kang; Sungpil Yoon
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

Review 6.  p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Authors:  Christie Rodriguez-Ramirez; Jacques E Nör
Journal:  Crit Rev Oncog       Date:  2018

7.  Salinomycin and other polyether ionophores are a new class of antiscarring agent.

Authors:  Collynn F Woeller; Charles W O'Loughlin; Elisa Roztocil; Steven E Feldon; Richard P Phipps
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 8.  The Valley of Death in anticancer drug development: a reassessment.

Authors:  David J Adams
Journal:  Trends Pharmacol Sci       Date:  2012-03-10       Impact factor: 14.819

Review 9.  Salinomycin: a novel anti-cancer agent with known anti-coccidial activities.

Authors:  Shuang Zhou; Fengfei Wang; Eric T Wong; Ekokobe Fonkem; Tze-Chen Hsieh; Joseph M Wu; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

10.  Salinomycin may inhibit the cancer stem-like populations with increased chemoradioresistance that nasopharyngeal cancer tumorspheres contain.

Authors:  Gong Zhang; Shuping Zhang; Jinjin Ren; Chunxiao Yao; Zhongren Zhao; Xiurong Qi; Xiaofeng Zhang; Shuye Wang; Lei Li
Journal:  Oncol Lett       Date:  2018-06-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.